Idiopathic Pulmonary Fibrosis — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE).
Lang David et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41852279/
- 2.
Dual knockdown of Alox15 and TGF-β1 by lipid nanoparticle-delivered siRNA in bleomycin-induced pulmonary fibrosis.
Chang Chia-Wei et al. — Biochemistry and biophysics reports (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41847300/
- 3.
GRN and KLRB1 define a shared peripheral-blood transcriptomic signature linking SLE and IPF.
Pang Lijun et al. — Journal of translational autoimmunity (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41782635/
- 4.
Study on the anti-pulmonary fibrosis mechanism of Renshen Pingfei formula by inhibiting M2 macrophage polarization and regulating TGF - β/SMAD signaling pathway.
Hong Lingling et al. — Journal of ethnopharmacology (23 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41780616/
- 5.
Sinominine alleviates pulmonary fibrosis by suppressing macrophage-to-myofibroblast transition via inhibition of the Frem1/NF-κB/IL-1β axis.
Zheng Junhui et al. — International immunopharmacology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41833105/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease
Recruiting — Na — University of Sydney
https://clinicaltrials.gov/study/NCT06122233
- 2.
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Recruiting — Phase 2 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT07036523
- 3.
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Recruiting — University of Massachusetts, Worcester
https://clinicaltrials.gov/study/NCT06855329
- 4.
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Recruiting — Phase 3 — GlaxoSmithKline
https://clinicaltrials.gov/study/NCT06572384
- 5.
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting — Phase 2 — Syndax Pharmaceuticals
https://clinicaltrials.gov/study/NCT06132256
- 6.
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT06238622
- 7.
Treatable Traits in Interstitial Lung Disease
Recruiting — Na — The University of Western Australia
https://clinicaltrials.gov/study/NCT06626438
- 8.
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Recruiting — Phase 2 — Avalyn Pharma Inc.
https://clinicaltrials.gov/study/NCT06951217
- 9.
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Recruiting — Phase 2 — Avalyn Pharma Inc.
https://clinicaltrials.gov/study/NCT06329401
- 10.
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Recruiting — Phase 2 — GlaxoSmithKline
https://clinicaltrials.gov/study/NCT05878717
- 11.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting — Phase 3 — United Therapeutics
https://clinicaltrials.gov/study/NCT05943535
- 12.
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Recruiting — Phase 2 — Vicore Pharma AB
https://clinicaltrials.gov/study/NCT06588686
- 13.
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
Recruiting — Phase 1 — Shenzhen Resproly Biopharmaceutical Co., Ltd
https://clinicaltrials.gov/study/NCT06482190
- 14.
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting — Phase 2 — Mediar Therapeutics
https://clinicaltrials.gov/study/NCT06967805
- 15.
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT06806592
- 16.
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT07201922
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which scar tissue builds up in the lungs, making breathing increasingly difficult. The cause is unknown and it predominantly affects adults over 50. Three antifibrotic medicines can slow progression, and research into new treatments is advancing rapidly. An estimated 8,500 Australians live with IPF.
Most Recent Research
BACKGROUND AND OBJECTIVES: While recent data imply an association of statin use with improved prognosis in idiopathic pulmonary fibrosis (IPF), older reports suggested an increased risk of interstitial lung diseases development. We investigated the association of statin medication with survival and disease progression in the European MultiPartner IPF Registry (EMPIRE). PATIENTS AND METHODS: Patients with at least one year of follow-up and documented statin and/or antifibrotic treatment status from registry inclusion on were selected. Overall- and event-free survival (OS/EFS) were assessed, EFS was defined as either decline in ≥10% predicted relative forced vital capacity (FVC), ≥15% in diffusion capacity for carbon monoxide (DLCO), IPF exacerbation, respiratory hospitalization, and all-cause death. Results were adjusted for sex, age, baseline FVC, antifibrotic treatment status, presence of cardiovascular disease including diabetes, and time since IPF diagnosis. RESULTS: Of 2,669 patients selected, 739 (27.7%) reported statin use and had longer OS than non-users (HR 0.79 (95% CI 0.69-0.9, p < 0.001). Adjusted OS however did not differ by statin use vs. non-use (HR 0.90 (95% CI 0.78-1.04), p = 0.16). In exploratory subgroup analyses according to statin and antifibrotic treatment status, significant differences in unadjusted OS were observed in patients not receiving antifibrotics (statin present vs. absent, HR 0.64 (95% CI 0.5-0.81), p < 0.001)), but not after adjusting for covariates. There were no meaningful differences in EFS according to statin treatment with or without concurrent antifibrotics. CONCLUSIONS: We did not observe significant associations of statin treatment with outcomes in IPF patients in the EMPIRE registry.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.